The expensive, innovative medication “Trikafta” for the treatment of the progressive genetic disease, cystic fibrosis, is in Georgia. The distribution of the drug for beneficiaries meeting the relevant criteria will begin in the nearest days.

Integrating Trikafta into the national healthcare programme marks a transformative step for individuals living with cystic fibrosis in Georgia. By targeting the disease’s underlying genetic cause, the drug improves lung function, reduces acute flare-ups, and lowers hospital admission risks, significantly extending life expectancy and quality of life.

Patients eligible for the treatment have already begun pre-therapy medical evaluations. Clinicians are currently assessing patient baseline health and treatment readiness to ensure safe administration and plan ongoing medical monitoring.

Cystic fibrosis is a progressive inherited condition that primarily damages the lungs and digestive system. Characterized by recurrent respiratory infections, it frequently leads to severe decline in lung function over time. The burden of continuous medical management and disease complications heavily impacts daily living, underscoring the critical need for advanced targeted therapies.

Mikheil Sarjveladze, Minister of Health, personally informed patients and their families a month ago that a procurement contract had been finalized directly with the manufacturer.

The medication is approved for patients aged two and older who possess specific genetic mutations endorsed by the US Food and Drug Administration and the European Medicines Agency.

Around 110 persons are currently registered with a cystic fibrosis diagnosis in Georgia, approximately 60 of whom carry the targeted genetic mutation required for Trikafta therapy.

The Ministry of Health, in active cooperation with the medical community, people with cystic fibrosis, and their family members, worked consistently to increase access to modern treatment.

For this purpose, the Ministry gradually expanded the list of services and medications funded under the state program. In 2025, inhalation drugs, antibiotics, vitamins, and other medications were added to the program, and funding for inpatient services was also increased.